FDA Clears Haemonetics 510(k) to Collect 2RBC from More Female Donors
BRAINTREE, Mass., Feb. 22 /PRNewswire-FirstCall/ -- On January 27, 2010 the FDA cleared the Haemonetics (NYSE: HAE) 510(k) for its expanded nomogram to collect two Red Blood Cells on the Cymbal® Automated Blood Collection System from female donors who are at least 150 pounds and are 63 inches in height. The Cymbal is a small, portable, battery operated instrument that automates blood collection from volunteer donors, improving process control and helping alleviate blood shortages.
This expanded nomogram is identical to the FDA cleared claim for Haemonetics' MCS®+ automated system to collect red cells. Prior to this new approval, donors utilizing the Cymbal technology had to be 150 pounds and 65 inches. This approval allows blood collectors to expand utilization of the Cymbal technology to 3-6% more female donors supporting the blood center's abilities to optimize donor collections.
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com .
CONTACT: Bryanne Salmon |
|
Tel. (781) 356-9613 |
|
SOURCE Haemonetics
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article